Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability Study of UBX1325 in Patients With Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* nAMD patients who, in the opinion of the Investigator, are inadequately responding to or failed current treatment options.~* Active choroidal neovascularization (CNV) associated with age-related macular degeneration as evidenced on FA and SD-OCT at Day 1, including presence of intraretinal or subretinal fluid.~* BCVA in the study eye (most affected) of 70 Early Treatment Diabetic Retinopathy Study (ETDRS) letters or worse at screening and on Day 1.~* Patients who have the capacity to give informed consent and who are willing and able to comply with all study-related procedures and assessments.~Exclusion Criteria:~* Any ocular/intraocular/periocular infection or inflammation in either eye in the past 4 weeks prior to screening.~* Subretinal hemorrhage with bleeding area ≥4 disc area in the study eye~* Concomitant therapy with anti-VEGF therapies (e.g., Avastin®, Lucentis®, or Eylea®) or previous use of these agents in the study eye within approximately 28 days of study enrollment~* Any retinovascular disease or retinal degeneration other than nAMD in the study eye.~* History of systemic and intraocular steroid use for 6 months prior to Day 1. The use of intravitreal nonbiodegradable steroid implants (ex. Iluvien®, Yutiq®, Retisert®) is prohibited.~* Significant media opacities, including cataract, which might interfere with VA, assessment of toxicity, or fundus imaging.~* Any uncontrolled medical condition that, in the opinion of the investigator, would preclude participation in this study.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment with UBX1325 (Type: EXPERIMENTAL): UBX1325, single intravitreal injection, ascending dose

Based on this trial design, predict the completion outcome and termination type (if applicable).